Life expectancy of HIV-infected patients followed at the largest hospital in Guinea-Bissau is one-fourth of life expectancy of the background population.
Guinea-Bissau
HIV
HIV-2
Life expectancy
Loss to follow-up
Mortality
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
23
08
2020
accepted:
30
12
2020
pubmed:
3
2
2021
medline:
26
11
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
To estimate the life expectancy (LE) of HIV-infected patients in the West African country Guinea-Bissau and compare it with the background population. Using data from the largest HIV outpatient clinic at the Hospital Nacional Simão Mendes in the capital Bissau, a retrospective observational cohort study was performed. The study included patients attending the clinic between June 2005 and January 2018. A total of 8958 HIV-infected patients were included. In the analysis of the background population, a total of 109,191 people were included. LE incorporating loss to follow-up (LTFU) was estimated via Kaplan-Meier estimators using observational data on adult HIV-infected patients and background population. The LE of 20-year-old HIV-infected patients was 9.8 years (95% CI 8.3-11.5), corresponding to 22.3% (95% CI 18.5-26.7%) of the LE of the background population. (LE for 20-year-olds in the background population was 44.0 years [95% CI 43.0-44.9].) Patients diagnosed with CD4 cell counts below 200 cells/µL had a LE of 5.7 years (95% CI 3.6-8.2). No increase in LE with later calendar period of diagnosis was observed. LE was shown to be markedly lower among HIV-infected patients compared with the background population. While other settings have shown marked improvements in prognosis of HIV-infected patients in recent years, no improvement in Bissau was observed over time (9.8 years (95% CI 7.6-12.2) and 9.9 years (95% CI 7.6-12.1) for the periods 2005-2010 and 2014-2016, respectively).
Identifiants
pubmed: 33528814
doi: 10.1007/s15010-020-01574-6
pii: 10.1007/s15010-020-01574-6
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
631-643Subventions
Organisme : Aarhus Universitets Forskningsfond
ID : 22335
Investigateurs
Amabelia Rodrigues
(A)
David da Silva Té
(D)
Zacarias da Silva
(Z)
Candida Medina
(C)
Ines Oliviera-Souto
(I)
Lars Østergaard
(L)
Alex Laursen
(A)
Peter Aaby
(P)
Anders Fomsgaard
(A)
Christian Erikstrup
(C)
Bo Langhoff Hønge
(BL)
Christian Wejse
(C)
Sanne Jespersen
(S)
Informations de copyright
© 2021. Springer-Verlag GmbH, DE part of Springer Nature.
Références
Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146:87–95.
doi: 10.7326/0003-4819-146-2-200701160-00003
Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–56. https://doi.org/10.1016/S2352-3018(17)30066-8 .
doi: 10.1016/S2352-3018(17)30066-8
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185–97. https://doi.org/10.1097/QAD.0b013e328133f285 .
doi: 10.1097/QAD.0b013e328133f285
pubmed: 17502729
Hernandez-Avila JE, Palacio-Mejia LS, Hernandez-Romieu A, Bautista-Arredondo S, Sepulveda Amor J, Hernandez-Avila M. Implementation and operational research: effect of universal access to antiretroviral therapy on HIV/AIDS mortality in Mexico 1990–2011. J Acquir Immune Defic Syndr. 2015;69:e100–8. https://doi.org/10.1097/QAI.0000000000000645 .
doi: 10.1097/QAI.0000000000000645
pubmed: 25886921
Gueler A, Moser A, Calmy A, Gunthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS. 2017;31:427–36. https://doi.org/10.1097/QAD.0000000000001335 .
doi: 10.1097/QAD.0000000000001335
pubmed: 27831953
Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209–16. https://doi.org/10.7326/0003-4819-155-4-201108160-00358 .
doi: 10.7326/0003-4819-155-4-201108160-00358
pubmed: 21768555
Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418. https://doi.org/10.1371/journal.pmed.1001418 .
doi: 10.1371/journal.pmed.1001418
pubmed: 23585736
pmcid: 3621664
Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health. 2015;3:e169–77. https://doi.org/10.1016/S2214-109X(14)70364-X .
doi: 10.1016/S2214-109X(14)70364-X
pubmed: 25701995
Asiki G, Reniers G, Newton R, Baisley K, Nakiyingi-Miiro J, Slaymaker E, et al. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991–2012). AIDS. 2016;30:487–93. https://doi.org/10.1097/QAD.0000000000000930 .
doi: 10.1097/QAD.0000000000000930
pubmed: 26765939
Olesen JS, Jespersen S, Da Silva ZJ, Rodrigues A, Erikstrup C, Aaby P, et al. HIV-2 continues to decrease, while HIV-1 is stabilizing in Guinea-Bissau. AIDS. 2018. https://doi.org/10.1097/QAD.0000000000001827 .
doi: 10.1097/QAD.0000000000001827
pubmed: 29683842
Dyrehave C, Rasmussen DN, Honge BL, Jespersen S, Correia FG, Medina C, et al. Nonadherence is associated with lack of HIV-related knowledge: a cross-sectional study among HIV-infected individuals in Guinea-Bissau. J Int Assoc Provid AIDS Care. 2016;15:350–8. https://doi.org/10.1177/2325957415599211 .
doi: 10.1177/2325957415599211
pubmed: 26297492
Rasmussen DN, da Silva TD, Rodkjaer L, Oliveira I, Medina C, Barfod T, et al. Barriers and facilitators to antiretroviral therapy adherence among patients with HIV in Bissau, Guinea-Bissau: a qualitative study. Afr J AIDS Res. 2013;12:1–8. https://doi.org/10.2989/16085906.2013.815405 .
doi: 10.2989/16085906.2013.815405
pubmed: 25871305
Jespersen S, Tolstrup M, Honge BL, Medina C, Te Dda S, Ellermann-Eriksen S, et al. High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau. Virol J. 2015;12:41. https://doi.org/10.1186/s12985-015-0273-9 .
doi: 10.1186/s12985-015-0273-9
pubmed: 25889017
pmcid: 4357169
Jespersen S, Honge BL, Medina C, da Silva TD, Correira FG, Laursen AL, et al. Lack of awareness of treatment failure among HIV-1-infected patients in Guinea-Bissau—a retrospective cohort study. J Int AIDS Soc. 2015;18:20243. https://doi.org/10.7448/IAS.18.1.20243 .
doi: 10.7448/IAS.18.1.20243
pubmed: 26426197
pmcid: 4590343
Honge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, da Silva ZJ, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013;3:e003499. https://doi.org/10.1136/bmjopen-2013-003499 .
doi: 10.1136/bmjopen-2013-003499
pubmed: 24163204
pmcid: 3808780
Nordentoft PB, Engell-Sorensen T, Jespersen S, Correia FG, Medina C, da Silva TD, et al. Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau. Infection. 2017;45:187–97. https://doi.org/10.1007/s15010-016-0949-0 .
doi: 10.1007/s15010-016-0949-0
pubmed: 27743308
Jespersen S, Honge BL, Oliveira I, Medina C, da Silva TD, Correia FG, et al. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations. Bull World Health Organ. 2014;92:909–14. https://doi.org/10.2471/BLT.14.135749 .
doi: 10.2471/BLT.14.135749
pubmed: 25552775
pmcid: 4264391
Jespersen S, Honge BL, Oliveira I, Medina C, da Silva TD, Correira FG, et al. Cohort profile: the Bissau HIV cohort-a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol. 2015;44:756–63. https://doi.org/10.1093/ije/dyu201 .
doi: 10.1093/ije/dyu201
pubmed: 25342251
MICS5 Guinea-Bissau. UNICEF. 2014. https://mics.unicef.org/surveys .
Andersen A, Bjerregaard-Andersen M, Rodrigues A, Umbasse P, Fisker AB. Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. Vaccine. 2017;35:7018–25. https://doi.org/10.1016/j.vaccine.2017.10.047 .
doi: 10.1016/j.vaccine.2017.10.047
pubmed: 29107347
Guinea-Bissau Economic Report. The World Bank. https://data.worldbank.org/country/guinea-bissau .
WHO. Guinea-Bissau. 2016. https://www.who.int/countries/gnb/en/ .
van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F, Study Anoc. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–35. https://doi.org/10.1097/QAD.0b013e32833a3946 .
doi: 10.1097/QAD.0b013e32833a3946
pubmed: 20467289
Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274. https://doi.org/10.1186/s12879-015-0969-x .
doi: 10.1186/s12879-015-0969-x
pubmed: 26183704
pmcid: 4504463
Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53:124–30. https://doi.org/10.1097/QAI.0b013e3181b563e7 .
doi: 10.1097/QAI.0b013e3181b563e7
pubmed: 19730109
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28:1193–202. https://doi.org/10.1097/QAD.0000000000000243 .
doi: 10.1097/QAD.0000000000000243
pubmed: 24556869
Lohse N, Obel N. Update of survival for persons with HIV infection in Denmark. Ann Intern Med. 2016;165:749–50. https://doi.org/10.7326/L16-0091 .
doi: 10.7326/L16-0091
pubmed: 27842400
Esbjornsson J, Mansson F, Kvist A, Isberg PE, Biague AJ, da Silva ZJ, et al. Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. AIDS. 2014;28:949–57.
doi: 10.1097/QAD.0000000000000101
Prince PD, Matser A, van Tienen C, Whittle HC, Schim van der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS. 2014;28:549–58. https://doi.org/10.1097/01.SPC.0000432532.87841.78 .
doi: 10.1097/01.SPC.0000432532.87841.78
pubmed: 23921613
Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, Jaye A, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS. 2011;25:2167–75. https://doi.org/10.1097/QAD.0b013e32834c4adb .
doi: 10.1097/QAD.0b013e32834c4adb
pubmed: 21881480
Honge BL, Bjarnason Obinah MP, Jespersen S, Medina C, Te Dda S, da Silva ZJ, et al. Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr. 2014;65:87–90. https://doi.org/10.1097/QAI.0b013e3182a97b81 .
doi: 10.1097/QAI.0b013e3182a97b81
pubmed: 23982658
Honge BL, Jespersen S, Bjarnason Obinah MP, Medina C, da Silva TD, da Silva ZJ, et al. Interobserver variation of the rapid test SD bioline HIV-1/2 3.0 for HIV type discrimination: experiences from Guinea-Bissau. J Acquir Immune Defic Syndr. 2015;68:e23–5. https://doi.org/10.1097/QAI.0000000000000435 .
doi: 10.1097/QAI.0000000000000435
pubmed: 25415294
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016. https://doi.org/10.1136/bmj.d6016 .
doi: 10.1136/bmj.d6016
pubmed: 21990260
pmcid: 3191202
Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9. https://doi.org/10.1016/S0140-6736(08)61113-7 .
doi: 10.1016/S0140-6736(08)61113-7
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8:e81355. https://doi.org/10.1371/journal.pone.0081355 .
doi: 10.1371/journal.pone.0081355
pubmed: 24367482
pmcid: 3867319
Farahani M, Price N, El-Halabi S, Mlaudzi N, Keapoletswe K, Lebelonyane R, et al. Trends and determinants of survival for over 200,000 patients on antiretroviral treatment in the Botswana National Program: 2002–2013. AIDS. 2016;30:477–85. https://doi.org/10.1097/QAD.0000000000000921 .
doi: 10.1097/QAD.0000000000000921
pubmed: 26636931
Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69:98–108. https://doi.org/10.1097/QAI.0000000000000553 .
doi: 10.1097/QAI.0000000000000553
pubmed: 25942461
pmcid: 4422218
Honge BL, Jespersen S, Aunsborg J, Mendes DV, Medina C, da Silva TD, et al. High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau—a cohort study from West Africa. Pan Afr Med J. 2016;25:40. https://doi.org/10.11604/pamj.2016.25.40.8329 .
doi: 10.11604/pamj.2016.25.40.8329
pubmed: 28154729
pmcid: 5268749